Results 41 to 50 of about 77,938,455 (214)
Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
Objective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with Rifaximin. Study Design: Observational descriptive study.
Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
doaj
ABSTRACT ADNP‐related Helsmoortel–Van der Aa syndrome (ADNP‐related HVDAS) is a single gene form of autism spectrum disorder (ASD) caused by pathogenic sequence variants in the activity‐dependent neuroprotective protein (ADNP) gene. In addition to ASD, ADNP‐related HVDAS is associated with a wide range of cognitive, behavioral, and physical health ...
Jarrett Fastman +11 more
wiley +1 more source
Irritable Bowel Syndrome and Me: A Sworn Rivalry
“Three more hours”, I tell myself as I find my way to the exam hall. I see a bunch of my classmates cramming for the last minute, and here I am, in a corner, reminding myself that it’s just three more hours till I get away from this horror.
Selika Shakya
doaj +1 more source
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Irritable Bowel Syndrome: Diagnosis and Treatment [PDF]
Irritable bowel syndrome (IBS) is the most common functional disorder of the gastrointestinal tract. As a result of the lack of specific diagnostic testing and absence of circumscribed biology markers of the disease, its diagnosis is based on a myriad of
K, Marcellus Simadibrata +3 more
core +2 more sources
Safety of proton pump inhibitors in children: A systematic review
Aim To systematically evaluate the safety of proton pump inhibitor (PPI) therapy in children aged 0–12 years, with a focus on treatment‐emergent adverse events across different study designs and age groups. Method The systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA ...
Ahmad Raza Sachel +2 more
wiley +1 more source
The differences of various diarrhea symptoms between respondents with functional diarrhea and with diarrhea-predominant irritable bowel syndrome (IBS-D).
Zhan-Sai Zhang (310386) +6 more
core +1 more source
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin [PDF]
Christopher Chang1,2 1New Mexico VA Health Care System, Division of Gastroenterology and Hepatology, Albuquerque, NM, USA; 2Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA Abstract: Irritable bowel ...
Chang, Christopher +2 more
core +1 more source
Abstract Objectives The role of a low‐FODMAP diet in pediatric disorders of gut–brain interaction (DGBIs), particularly irritable bowel syndrome (IBS) and functional abdominal pain (FAP), is unclear. This review synthesized evidence on its efficacy in children and adolescents with IBS or FAP.
Pedro Henrique Silva de Oliveira Souza +6 more
wiley +1 more source
Health-related quality of life in individuals with functional diarrhea and with diarrhea-predominant irritable bowel syndrome.
Zhan-Sai Zhang (310386) +6 more
core +1 more source

